Pancreatic Cancer Research

ResearcherOkayama UniversityActive in the last 2 years

Kazuyuki Matsumoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5102-7452; OpenAlex author ID A5084984842. Sources: OpenAlex.

Their work

Papers
19 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: none · 2025: 7 papers · 2026: 1 paper

Papers 19

  1. Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer. Co-author DOI 10.1007/s00535-025-02321-0↗
  2. A case of pancreatic ductal adenocarcinoma growing within the pancreatic duct mimicking an intraductal tubulopapillary neoplasm. First author DOI 10.1007/s12328-025-02098-y↗
  3. Robotic posterior radical antegrade modular pancreatosplenectomy for left-sided pancreatic cancer using the ligament of Treitz first approach: A case report an… Co-author DOI 10.1016/j.ijscr.2025.111782↗
  4. Current status of endoscopic ultrasound-guided antitumor treatment for pancreatic cancer. Co-author DOI 10.1111/den.14815↗
  5. Precise stratification of prognosis in pancreatic ductal adenocarcinoma patients based on pre- and postoperative genomic information. Co-author DOI 10.1186/s12935-025-03894-9↗
  6. Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus S-1 in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers17203287↗
  7. Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up. Co-author DOI 10.7759/cureus.79001↗
  8. Correction: Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up. Co-author DOI 10.7759/cureus.c365↗
  9. Cysts or necrotic components in pancreatic ductal adenocarcinoma is associated with the risk of EUS-FNA/B complications including needle tract seeding. First author DOI 10.1016/j.pan.2023.10.018↗
  10. Association between BRCA Gene Variants and the Response to Modified FOLFIRINOX in Patients with Unresectable Pancreatic Cancer. First author DOI 10.18926/amo/65974↗
  11. Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer. Co-author DOI 10.1080/15384047.2021.1980312↗
  12. Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-Guided Fine-Needle Aspiration. Co-author DOI 10.1007/s10620-019-06006-6↗
  13. The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer. Co-author DOI 10.1007/s00535-019-01586-6↗
  14. Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/15384047.2019.1638685↗
  15. Diagnostic Ability of Convex-Arrayed Endoscopic Ultrasonography for Major Vascular Invasion in Pancreatic Cancer. First author DOI 10.5946/ce.2018.163↗
  16. Efficacy and safety of chemotherapy after endoscopic double stenting for malignant duodenal and biliary obstructions in patients with advanced pancreatic cance… Co-author DOI 10.1186/s12876-018-0886-8↗
  17. Preoperative Detection of Tumor Seeding after Endoscopic Ultrasonography-guided Fine Needle Aspiration for Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.0321-17↗
  18. Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue. Co-author DOI 10.1016/j.pan.2016.12.011↗
  19. Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients. Co-author DOI 10.1159/000330384↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hironari Kato · 15 shared papers, 2011–2025 · strength 2.11
  2. Shigeru Horiguchi · 13 shared papers, 2017–2025 · strength 1.90
  3. Motoyuki Otsuka · 7 shared papers, 2023–2025 · strength 1.68
  4. Yuki Fujii · 6 shared papers, 2019–2025 · strength 1.10
  5. Koichiro Tsutsumi · 6 shared papers, 2017–2025 · strength 1.07
  6. Kosei Takagi · 4 shared papers, 2025 · strength 1.01
  7. Kazuya Yasui · 3 shared papers, 2025 · strength 0.77
  8. Toshiyoshi Fujiwara · 3 shared papers, 2025 · strength 0.77
  9. Ryosuke Sato · 3 shared papers, 2025 · strength 0.74
  10. Daisuke Uchida · 7 shared papers, 2017–2023 · strength 0.65
  11. Hiroyuki Terasawa · 4 shared papers, 2019–2023 · strength 0.52
  12. Hiroyuki Okada · 5 shared papers, 2018–2020 · strength 0.47
  13. Yasuo Nagai · 2 shared papers, 2025 · strength 0.44
  14. Takeyoshi Nishiyama · 2 shared papers, 2025 · strength 0.44
  15. Shinichiro Muro · 5 shared papers, 2017–2021 · strength 0.42
  16. Yuzo Umeda · 3 shared papers, 2019–2025 · strength 0.38
  17. Ryuichi Yoshida · 3 shared papers, 2019–2025 · strength 0.38
  18. Soichiro Ako · 4 shared papers, 2017–2021 · strength 0.35
  19. Kazuhiro Nouso · 4 shared papers, 2017–2021 · strength 0.35
  20. Hideaki Kinugasa · 4 shared papers, 2017–2021 · strength 0.35
  21. Kokichi Miyamoto · 1 shared paper, 2025 · strength 0.19
  22. Kazuhiro Yoshida · 1 shared paper, 2025 · strength 0.19
  23. Hiroyuki Okada · 2 shared papers, 2018–2021 · strength 0.18
  24. Tatsuya Kikuchi · 1 shared paper, 2023 · strength 0.14
  25. Hiroyuki M. OKADA · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.